Results 11 to 20 of about 35,166 (278)

Genotoxic, neurotoxic and neuroprotective activities of apomorphine and its oxidized derivative 8-oxo-apomorphine [PDF]

Brazilian Journal of Medical and Biological Research, 2005
Apomorphine is a dopamine receptor agonist proposed to be a neuroprotective agent in the treatment of patients with Parkinson's disease. Both in vivo and in vitro studies have shown that apomorphine displays both antioxidant and pro-oxidant actions, and ...
J.N. Picada, R. Roesler, J.A.P. Henriques   +2 more
doaj   +2 more sources

Integrating technology into a successful apomorphine delivery program in Thailand: a 10-year journey of achievements with a five-motto concept. [PDF]

Front Neurol
IntroductionApomorphine, a potent dopamine agonist, is a therapeutic option for patients with Parkinson’s disease and motor fluctuations. However, the adoption of and adherence to this therapy have been limited by the need for complex delivery devices ...
Phokaewvarangkul O, Kantachadvanich N, Buranasrikul V, Sanyawut K, Phumphid S, Anan C, Bhidayasiri R.   +6 more
europepmc   +2 more sources

Non-Targeted Metabolomics Reveal Apomorphine's Therapeutic Effects and Lysophospholipid Alterations in Steatohepatitis. [PDF]

Antioxidants (Basel)
Metabolic dysfunction-associated steatohepatitis (MASH), characterized by progressive inflammation and fibrosis, evolves from metabolic dysfunction-associated steatotic liver disease and significantly heightens the risk of cirrhosis and hepatocellular ...
Ogiso H, Miura K, Nagai R, Osaka H, Aizawa K.   +4 more
europepmc   +2 more sources

The Pharmacological Properties and Therapeutic Use of Apomorphine

Molecules, 2012
Apomorphine <strong>(</strong>APO) is an aporphine derivative used in human and veterinary medicine. APO activates D₁, D_2S, D_2L, D₃, D<sub>4</
Samo Ribarič
doaj   +2 more sources

Synthetic aporphine alkaloids are potential therapeutics for Leigh syndrome. [PDF]

Sci Rep
Mitochondrial diseases are mainly caused by dysfunction of mitochondrial respiratory chain complexes and have a variety of genetic variants or phenotypes. There are only a few approved treatments, and fundamental therapies are yet to be developed.
Kobayashi M, Miyauchi A, Jimbo EF, Oishi N, Aoki S, Watanabe M, Yoshikawa Y, Akiyama Y, Yamagata T, Osaka H.   +9 more
europepmc   +2 more sources

Gender disparity in access to advanced therapies for patients with Parkinson's disease: a retrospective real-word study. [PDF]

Front Neurol
BackgroundGender differences in the access to advanced therapies for Parkinson’s disease (PD) are poorly investigated.ObjectiveThe objective of this study was to investigate the presence of any gender disparity in the access to advanced therapies for PD ...
Maccarrone G, Saporito G, Sucapane P, Rizi C, Bruno F, Catalucci A, Pistoia ML, Splendiani A, Ricci A, Di Cesare E, Rizzo M, Totaro R, Pistoia F.   +12 more
europepmc   +2 more sources

APOMORPHINE

Anaesthesia, 1978
E.M. PITT
openalex   +3 more sources

Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson’s Disease and “OFF” Episodes: Results of a Randomized, Three-Way Crossover, Open-Label Study

Neurological Therapeutics, 2021
In a pivotal study, apomorphine sublingual film (APL; KYNMOBI®) was an effective and generally well-tolerated on-demand treatment of “OFF” episodes in patients with Parkinson’s disease (PD), approved across the dose range of 10–30 mg.
F. Agbo, S. Isaacson, R. Gil, Y. Chiu, S. Brantley, P. Bhargava, B. Navia   +6 more
semanticscholar   +1 more source

Population pharmacokinetic analysis of apomorphine sublingual film or subcutaneous apomorphine in healthy subjects and patients with Parkinson’s disease

Clinical and Translational Science, 2021
Apomorphine is an on‐demand treatment of “OFF” episodes in patients with Parkinson’s disease (PD). A joint parent‐metabolite population pharmacokinetic (PK) model characterized apomorphine and apomorphine‐sulfate following administration of apomorphine ...
Felix Agbo, Ryan L. Crass, Yu‐Yuan Chiu, Sunny Chapel, Gerald Galluppi, David Blum, Bradford Navia   +6 more
doaj   +1 more source

Ankk1 Loss of Function Disrupts Dopaminergic Pathways in Zebrafish

Frontiers in Neuroscience, 2022
Ankyrin repeat and kinase domain containing 1 (ANKK1) is a member of the receptor-interacting protein serine/threonine kinase family, known to be involved in cell proliferation, differentiation and activation of transcription factors.
Adele Leggieri, Judit García-González, Jose V. Torres-Perez, William Havelange, Saeedeh Hosseinian, Aleksandra M. Mech, Marcus Keatinge, Elisabeth M. Busch-Nentwich, Elisabeth M. Busch-Nentwich, Caroline H. Brennan   +9 more
doaj   +1 more source